Indoco Remedies Limited (INDOCO.BO)
INR 235.05
(0.45%)
INR 235.05
(0.45%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 984.6 Million INR | -30.78% |
| 2022 | 1.42 Billion INR | -8.11% |
| 2021 | 1.54 Billion INR | 66.37% |
| 2020 | 930.45 Million INR | 285.8% |
| 2019 | 241.17 Million INR | 930.49% |
| 2018 | -29.04 Million INR | -107.06% |
| 2017 | 411.61 Million INR | -46.59% |
| 2016 | 770.61 Million INR | -5.95% |
| 2015 | 819.39 Million INR | -1.05% |
| 2014 | 828.12 Million INR | 42.83% |
| 2013 | 579.81 Million INR | 35.73% |
| 2012 | 427.18 Million INR | -7.82% |
| 2011 | 463.42 Million INR | -9.34% |
| 2010 | 511.17 Million INR | 21.44% |
| 2009 | 420.92 Million INR | 33.88% |
| 2008 | 314.41 Million INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 420.38 Million INR | 48.11% |
| 2005 | 283.83 Million INR | 13.34% |
| 2004 | 250.42 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 26.2 Million INR | -88.46% |
| 2024 Q2 | -95.7 Million INR | -465.27% |
| 2023 Q2 | 350.8 Million INR | 43.83% |
| 2023 Q1 | 243.9 Million INR | -5.5% |
| 2023 FY | 984.7 Million INR | -30.78% |
| 2023 Q4 | 227 Million INR | 39.26% |
| 2023 Q3 | 163 Million INR | -53.53% |
| 2022 FY | 1.42 Billion INR | -8.11% |
| 2022 Q1 | 385.7 Million INR | -4.65% |
| 2022 Q2 | 497.3 Million INR | 28.93% |
| 2022 Q3 | 281.5 Million INR | -43.39% |
| 2022 Q4 | 258.1 Million INR | -8.31% |
| 2021 Q2 | 416.9 Million INR | 5.12% |
| 2021 Q1 | 396.6 Million INR | 58.67% |
| 2021 FY | 1.54 Billion INR | 66.37% |
| 2021 Q3 | 329.9 Million INR | -20.87% |
| 2021 Q4 | 404.49 Million INR | 22.61% |
| 2020 FY | 930.45 Million INR | 285.8% |
| 2020 Q1 | 170.4 Million INR | 218.06% |
| 2020 Q4 | 249.95 Million INR | -1.44% |
| 2020 Q3 | 253.6 Million INR | -1.13% |
| 2020 Q2 | 256.5 Million INR | 50.53% |
| 2019 FY | 241.17 Million INR | 930.49% |
| 2019 Q3 | 91 Million INR | 16.52% |
| 2019 Q1 | 18.5 Million INR | -83.88% |
| 2019 Q4 | 53.57 Million INR | -41.13% |
| 2019 Q2 | 78.1 Million INR | 322.16% |
| 2018 Q3 | 52.7 Million INR | 170.74% |
| 2018 Q1 | -121.9 Million INR | 0.0% |
| 2018 FY | -29.04 Million INR | -107.06% |
| 2018 Q4 | 114.76 Million INR | 117.76% |
| 2018 Q2 | -74.5 Million INR | 38.88% |
| 2017 FY | 411.61 Million INR | -46.59% |
| 2016 FY | 770.61 Million INR | -5.95% |
| 2015 FY | 819.39 Million INR | -1.05% |
| 2014 Q1 | 200.4 Million INR | 0.0% |
| 2014 FY | 828.12 Million INR | 42.83% |
| 2013 Q1 | 91.8 Million INR | -28.88% |
| 2013 FY | 579.81 Million INR | 35.73% |
| 2012 Q4 | 129.08 Million INR | 0.0% |
| 2012 FY | 427.18 Million INR | -7.82% |
| 2011 FY | 463.42 Million INR | -9.34% |
| 2010 FY | 511.17 Million INR | 21.44% |
| 2009 FY | 420.92 Million INR | 33.88% |
| 2008 FY | 314.41 Million INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | 420.38 Million INR | 48.11% |
| 2005 FY | 283.83 Million INR | 13.34% |
| 2004 FY | 250.42 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 84.012% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 96.897% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 79.091% |
| Granules India Limited | 4.05 Billion INR | 75.707% |
| Achyut Healthcare Limited | 5.73 Million INR | -17077.268% |
| Ajanta Pharma Limited | 8.16 Billion INR | 87.936% |
| Alkem Laboratories Limited | 17.95 Billion INR | 94.517% |
| Alpa Laboratories Limited | 167.76 Million INR | -486.893% |
| Brooks Laboratories Limited | -195.91 Million INR | 602.555% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 39.038% |
| Bajaj HealthCare Limited | -837.93 Million INR | 217.504% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -30.49% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 98.232% |
| Eris Lifesciences Limited | 3.91 Billion INR | 74.882% |
| FDC Limited | 3.05 Billion INR | 67.742% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 106.557% |
| Gufic Biosciences Limited | 861.35 Million INR | -14.308% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 76.611% |
| Ipca Laboratories Limited | 5.47 Billion INR | 82.011% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -338.321% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 599.078% |
| Lasa Supergenerics Limited | -217.3 Million INR | 553.094% |
| Laurus Labs Limited | 1.6 Billion INR | 38.673% |
| Lupin Limited | 19.14 Billion INR | 94.857% |
| Mankind Pharma Limited | 19.12 Billion INR | 94.853% |
| Medicamen Biotech Limited | 109.31 Million INR | -800.742% |
| Medico Remedies Limited | 82.9 Million INR | -1087.568% |
| Megasoft Limited | -127.46 Million INR | 872.442% |
| NATCO Pharma Limited | 13.88 Billion INR | 92.908% |
| Piramal Pharma Limited | 178.2 Million INR | -452.526% |
| RPG Life Sciences Limited | 876.6 Million INR | -12.32% |
| Sigachi Industries Limited | 571.8 Million INR | -72.193% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 98.972% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 67.211% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -288.952% |
| Unichem Laboratories Limited | -704.74 Million INR | 239.711% |
| Wanbury Limited | 559.56 Million INR | -75.959% |
| Windlas Biotech Limited | 581.87 Million INR | -69.213% |
| ZIM Laboratories Limited | 172.46 Million INR | -470.902% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 97.449% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 125.428% |
| Divi's Laboratories Limited | 16 Billion INR | 93.846% |
| Hester Biosciences Limited | 188.89 Million INR | -421.256% |
| Procter & Gamble Health Limited | 2 Billion INR | 51.01% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -118.934% |
| Bal Pharma Limited | 73.92 Million INR | -1231.946% |
| Strides Pharma Science Limited | -706.14 Million INR | 239.434% |
| Venus Remedies Limited | 284.9 Million INR | -245.586% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 54.606% |
| Nectar Lifesciences Limited | 49.95 Million INR | -1871.173% |
| Shilpa Medicare Limited | 318.74 Million INR | -208.902% |
| Aarti Drugs Limited | 1.71 Billion INR | 42.561% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 26.757% |
| Suven Life Sciences Limited | -1.05 Billion INR | 193.703% |
| Ind-Swift Limited | 142.31 Million INR | -591.856% |
| Valiant Laboratories Limited | 3.19 Million INR | -30707.29% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 82.183% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 117.353% |
| Themis Medicare Limited | 435.23 Million INR | -126.221% |
| Hikal Limited | 696.02 Million INR | -41.462% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 94.056% |
| Sequent Scientific Limited | -358.69 Million INR | 374.499% |
| Novartis India Limited | 851.9 Million INR | -15.577% |
| Wockhardt Limited | -4.63 Billion INR | 121.266% |
| Jubilant Pharmova Limited | 771 Million INR | -27.704% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -13783.263% |
| Neuland Laboratories Limited | 3 Billion INR | 67.189% |
| Morepen Laboratories Limited | 961.59 Million INR | -2.392% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -574.32% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1185.354% |